Biotech Exec Settles Over Trades Ahead Of Novartis Deal

Law360, New York (August 20, 2012, 7:15 PM EDT) -- A former manager at Array BioPharma Inc., a Colorado-based developer of cancer drugs, agreed Monday to settle allegations brought by the U.S. Securities and Exchange Commission that he illegally traded on insider information about a pending partnership agreement with Swiss drugmaker Novartis AG.

In a civil complaint, the SEC charged James Lieberman, formerly manager of environmental health and safety at Array, with one count of securities fraud, alleging he bought Array shares within minutes of receiving an email about the Novartis deal from his supervisor....
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Securities and Exchange Commission v. Lieberman


Case Number

1:12-cv-02198

Court

Colorado

Nature of Suit

Securities/Commodities

Judge

William J. Martinez

Date Filed

August 20, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.